glp-1 cardiovascular outcome trials receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs | Diabetology GLP-1 Agonists in Cardiovascular Diseases:
Description
Efpeglenatide and cardiovascular outcomes in type 2 diabetes
2018;13(5):e0198024
Surg Obes Relat Dis (2018) 14(3):25963.10.1016/j.soard.2017.12.013 10 BuchwaldHAvidorYBraunwaldEJensenMDPoriesWFahrbachKet alBariatric surgery: a systematic review and meta-analysis
Protein requirements become critical Both menopause and GLP-1-induced weight loss put muscle mass at risk
The keto question Some GLP-1 users explore ketogenic diets alongside semaglutide as a stall-breaking strategy
The answer lies in the psychology of diabetes
